



A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents

11/08/2025 13:10:04

## Main Information

**Primary registry identifying number**

LBCTR2019010183

**Protocol number**

CLBH589D2222

**MOH registration number**

5241/ص

**Study registered at the country of origin**

Yes

**Study registered at the country of origin: Specify****Type of registration**

Retrospective

**Type of registration: Justify**

LCTR was already initiated, original file was previously submitted by Paper

**Date of registration in national regulatory agency**

12/07/2016

**Primary sponsor**

SecuraBio

**Primary sponsor: Country of origin**

SecuraBio

**Date of registration in primary registry**

13/08/2020

**Date of registration in national regulatory agency**

12/07/2016

**Public title**

A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents

**Acronym**

PANORAMA 3

**Scientific title**

"A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents"

**Acronym****Brief summary of the study: English**



## Brief Summary:

The purpose of this study is to investigate the safety and efficacy of three different regimens of PAN (20 mg TIW, 20 mg BIW, and 10 mg TIW) in combination with s.c. BTZ and Dex and to provide exposure, safety and efficacy data to identify the optimal regimen of PAN in a randomized, 3-arm parallel design. This study will also assess the impact of administering s.c. BTZ (in combination with PAN and Dex) twice weekly for 4 cycles, and then weekly starting from Cycle 5 until disease progression in patients  $\leq 75$  years of age. Patients  $> 75$  years of age will receive for the entire treatment period s.c. BTZ weekly (in combination with PAN and Dex) until disease progression.

Patients will be treated until disease progression or until they discontinue earlier due to unacceptable toxicity or for other reasons.

Patients who discontinued study treatment for reasons other than disease progression will be followed for efficacy every 6 weeks.

All patients will be followed for survival until the last patient entering long-term follow-up has completed a 3 year survival follow-up or discontinued earlier.

## Brief summary of the study: Arabic

دراسة مرحلة ثانية متعددة المراكز و عشوائية التوزيع ومفتوحة اللصاقة لتقييم سلامة وفعالية أنظمة علاجية مختلفة من بانوبينوستات عن طريق الفم بالاشتراك مع بورتيزوميب تحت الجلد وديكساميثازون عن طريق الفم لدى مرضى مصابين بالورم النقوي المتعدد المعاد أو المعاد/المقاوم للعلاج تعرضوا في السابق لأدوية مناعية مكثفة

## Health conditions/problem studied: Specify

Patient with Relapsed or Relapsed-and-refractory Multiple Myeloma

## Interventions: Specify

Drug: Panobinostat capsules  
Drug: bortezomib injection  
Drug: dexamethasone tablets

## Key inclusion and exclusion criteria: Inclusion criteria

Inclusion Criteria:

- multiple myeloma as per IMWG 2014 definition
- requiring treatment for relapsed or relapsed/refractory disease
- measurable disease based on central protein assessment
- 1 to 4 prior lines of therapy
- prior IMiD exposure
- acceptable lab values prior to randomization

## Key inclusion and exclusion criteria: Gender

Both

## Key inclusion and exclusion criteria: Specify gender

## Key inclusion and exclusion criteria: Age minimum

18

## Key inclusion and exclusion criteria: Age maximum

99

## Key inclusion and exclusion criteria: Exclusion criteria

Exclusion Criteria:

- primary refractory myeloma
- refractory to bortezomib
- concomitant anti-cancer therapy (other than BTZ/Dex and bisphosphonates)
- prior treatment with DAC inhibitors
- Clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months prior to randomization)
- Unresolved diarrhea  $\geq$  CTCAE grade 2 or presence of medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease)

Other protocol-defined inclusion/exclusion criteria may apply.

## Type of study

Interventional

**Type of intervention**

Pharmaceutical

**Type of intervention: Specify type**

N/A

**Trial scope**

Other

**Trial scope: Specify scope**
**Study design: Allocation**

Randomized controlled trial

**Study design: Masking**

Open (masking not used)

**Study design: Control**

Dose comparison

**Study phase**

2

**Study design: Purpose**

Treatment

**Study design: Specify purpose**

N/A

**Study design: Assignment**

Parallel

**Study design: Specify assignment**

N/A

**IMP has market authorization**

Yes, Worldwide

**IMP has market authorization: Specify**

Both US FDA and EU approved

**Name of IMP**

Panobinostat ( FARYDAK)

**Year of authorization**

2015

**Month of authorization**

2

**Type of IMP**

Others

**Pharmaceutical class**

Panobinostat has been developed as a pan-HDAC inhibitor of Class I, II and IV histone deacetylases (HDACs) involved in the deacetylation of histone and non-histone cellular proteins.

**Therapeutic indication**

patients with relapsed or relapsed/refractory multiple myeloma

**Therapeutic benefit**

Overall response rate (ORR) up to 8 cycles

**Study model**

N/A

**Study model: Explain model**

N/A

**Study model: Specify model**

N/A

**Time perspective**

N/A

**Time perspective: Explain time perspective**

N/A

**Time perspective: Specify perspective**

N/A

**Target follow-up duration**
**Target follow-up duration: Unit**
**Number of groups/cohorts**

## Biospecimen retention

Samples with DNA\*\*

## Biospecimen description

Samples will be sent to Covance central Lab in Switzerland as per study protocol to assess patient disease response following treatment administration.

## Target sample size

9

## Actual enrollment target size

9

## Date of first enrollment: Type

Actual

## Date of first enrollment: Date

10/05/2017

## Date of study closure: Type

Actual

## Date of study closure: Date

04/02/2020

## Recruitment status

Complete

## Recruitment status: Specify

## Date of completion

31/01/2019

## IPD sharing statement plan

No

## IPD sharing statement description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

## Additional data URL

<https://clinicaltrials.gov/ct2/show/NCT02654990?term=clbh589d2222&rank=1>

## Admin comments

## Trial status

Approved

## Secondary Identifying Numbers

Full name of issuing authority	Secondary identifying number
National Institute of Health (clinicaltrials.gov)	NCT02654990

## Sources of Monetary or Material Support

Name
Securabio



## Secondary Sponsors

Name

NA

## Contact for Public/Scientific Queries

Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Fadi Farhat	Saida	Lebanon	+961 3 753 155	drfadi.trials@gmail.com	Hammoud Hospital
Scientific	Hind Khairallah	Beirut	Lebanon	+961 1 512002 Ext. 271	Hind.Khairallah@fattal.com.lb	Khalil Fattal et Fils s.a.l.
Public	Fadi El Karak	Mansourieh	Lebanon	+961 3 061 621	felkarak@yahoo.com	Bellevue Medical Center
Public	Joseph Kattan	Beirut	Lebanon	+961 1424942	jkattan62@hotmail.com	Hotel Dieu De France

## Centers/Hospitals Involved in the Study

Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Hammoud Hospital	Dr Fadi Farhat	Hematology Oncology	Approved
Bellevue Medical Center	Dr Fadi El Karak	Hematology Oncology	Approved
Hotel Dieu De France	Dr Joseph Kattan	Hematology Oncology	Approved

## Ethics Review

Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Hotel Dieu de France	07/04/2016	Joseph Kattan	jkattan62@hotmail.com	009613635913
Bellevue Medical Center	22/08/2016	Fadi El Karak	felkarak@yahoo.com	00961 3 061 621
Hammoud Hospital University Medical Center	08/05/2017	Fadi Farhat	drfadi.trials@gmail.com	00961 3 753 155



Countries of Recruitment	
Name	
Lebanon	
Republic of Korea	
Netherlands	
Norway	
Poland	
Portugal	
Russian Federation	
Spain	
Sweden	
Thailand	
Australia	
Belgium	
Brazil	
Canada	
Czech Republic	
France	
Germany	
Greece	
Hungary	
Italy	
Turkey	
United States of America	



## Health Conditions or Problems Studied

Condition	Code	Keyword
Multiple myeloma	Multiple myeloma (C90.0)	MM

## Interventions

Intervention	Description	Keyword
Reference table 7.1 of the study protocol: History taking/ Lab procedures/ Radiology assessment/ medication administration/ ECG / Questionnaire completion/ Bone marrow aspirate procedure/ Assessment of adverse events	Informed consent form	ICF/ Blood test/ Vital signs

## Primary Outcomes

Name	Time Points	Measure
1.Overall response rate (ORR) up to 8 cycles	[ Time Frame: up to 8 cycles per patient, approximately 30 months ]	up to 8 cycles

## Key Secondary Outcomes

Name	Time Points	Measure
overall response rate	through out study	Through out the study
Progression-free survival	Progression free survival	PFS



## Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files